Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 14, 2025, MacroGenics, Inc. (the “ Company”) and Stephen Eck, M. D., Ph. D., Senior Vice President, Clinical Development and Chief Medical Officer of the Company, mutually agreed that Dr. Eck would depart the Company, effective as of December 31, 2025. In connection with Dr. Eck's departure, oversight of the clinical development function will be assumed on an interim basis by Frank Perabo, M. D., Ph. D., Vice President, Clinical Development. The Company has engaged an executive recruiter to conduct a search for a new Chief Medical Officer. Since joining MacroGenics in July 2020 as Senior Vice President, Clinical Development and Chief Medical Officer, Dr. Eck has led the Company’s clinical development efforts across multiple studies, and the Company thanks him for his service. In connection with Dr. Eck’s departure, he will receive the payments and benefits pursuant to a qualifying termination as set forth in his employment agreement with the Company (the “ Employment Agreement”), as described in the Company’s proxy statement filed with the Securities and Exchange Commission on April 11, 2025, subject to the terms and conditions of the Employment Agreement, including, without limitation, his signing of an effective general release and waiver of claims (the “ Release”) and compliance with the terms of the Release and his restrictive covenant obligations owed to the Company. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 20, 2025 MACROGENICS, INC. ───────────────────────────────────────────────────────────────────────────────────────────────── By: /s/ Jeffrey Peters